Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained?

Monoclonal antibodies bevacizumab and cetuximab both improve overall survival (OS), progression free survival (PFS) and overall response rate (ORR) when combined with irinotecan-containing regimens. The optimal sequence of these monoclonal antibodies in combination with chemotherapy is controversial...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Grande, Roberta, Gemma, Donatello, Sperduti, Isabella, Gelibter, Alain, Giampaolo, Maria Anna, Trombetta, Giorgio, Nelli, Fabrizio, Gamucci, Teresa
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer International Publishing AG 2013
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3647091/
https://ncbi.nlm.nih.gov/pubmed/23667824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2193-1801-2-185
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg